PCPA

As a result of these collective efforts, the standalone pCPA organization was established in late 2022, and the transition was completed in 2023. The new organization builds on the important work accomplished by the dedicated team of pCPA staff. The new organizational structure, along with an increase in internal capacity, will allow the pCPA to lead and support more product negotiations on behalf of member jurisdictions in the years ahead... The pCPA team works closely with the jurisdictions providing support in negotiations, administration, communications, standardization, analytics, process design, and policy related to brand and generic products... OverviewHistoryVision and MandateWhere pCPA Fits in the ProcesspCPA TeamOverviewThrough collective negotiations, the pan-Canadian Pharmaceutical Alliance has realized overall savings (as of April 2024) of $3.14 billion annually for brand name drugs and $750 million annually for generic drugs totaling $3.89 billion in annualized..